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The Wiskott-Aldrich syndrome (WAS) could be a rare X-linked primary 
 immunodeficiency disorder characterized by recurrent infections, eczema, and 
bleeding following thrombocytopenia. Despite the rarity of this syndrome, today 
our understanding of the cellular and molecular basis of the pathogenesis of this 
disease has increased and it’s well established that this disorder encompasses a wide 
range of clinical disorders including immunodeficiency, atopy, autoimmunity, 
and cancer. Wiskott–Aldrich Syndrome protein (WASP) mutations are located 
throughout the gene and inhibit or regulate the conventional function of WASP. 
Thus classic WAS occurs when WASP is absent, X-linked thrombocytopenia when 
mutated WASP is expressed, and X-linked neutropenia when missense mutations 
occur within the Cdc42-binding site. Developments within the use of diagnostic 
tools, supportive care, and advances in allogeneic hematopoietic cell transplanta-
tion have remarkably reduced the mortality related to this disorder. Besides, gene 
therapy has provided optimistic perspectives on the treatment approaches of those 
patients.
Keywords: Primary immunodeficiency, Wiskott-Aldrich Syndrome, X-linked 
thrombocytopenia, X-linked neutropenia, Hematopoietic cell transplantation,  
Gene therapy
1. Introduction
Wiskott-Aldrich syndrome (WAS) is a rare X-linked recessive disorder that is 
defined in three categories consist of severe immunodeficiency, thrombocytopenia, 
and eczema. Moreover, high frequency of lymphomas (mainly B cell origin), sus-
ceptibility to autoimmune diseases, recurrent infections, variable defects in B and 
T-lymphocyte function ,and bloody diarrhea are classified as other symptoms [1]. 
A genetic mutation in the WAS gene encoding Wiskott-Aldrich syndrome protein 
(WASp) affecting the immune system and leads to immunodeficiency. There is 
broad-spectrum depending on gene mutations ranging from severe phenotype 
(Classic WAS) to mild ones which consist of X-linked thrombocytopenia (XLT) 
and X-linked neutropenia (XLN) [2, 3]. The purpose of this chapter is to discuss 
WASp function, clinical and pathological manifestations associated with mutations 
of the WAS gene as well as a comprehensive review of WAS clinical diagnosis and 
treatment methods and their complications. In addition, a range of therapeutic 
approaches will be discussed, including the use of allogeneic hematopoietic stem 
cell (HCT) transplantation and gene therapy.
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2. Etiology
Wiskott-Aldrich syndrome is caused by mutations of the gene WASP (WAS 
protein) involved in actin polymerization, cellular signaling, cytoskeletal rear-
rangement, and immunological synapse formation. These mutations cause changes 
in protein structure by different mechanisms and lead to different phenotypes of 
this disease [1, 2].
3. Epidemiology
It has been estimated that one in every 100,000 male births leads to Wiskott-
Aldrich Syndrome, and in families without a history of the disease, the average age 
of diagnosis is 24 months [4, 5]. In the United States, the estimated incidence of 
WAS is one in 250,000 male births. Whereas WAS still is a rare disease, it is more 
common than other immunodeficiency syndromes such as hyper-IgM syndrome 
or SCID which have an estimated incidence of about one in 1,000,000 live births. 
It is thought WAS accounts for 1.2% of all inherited immunodeficiencies in the 
United States [6]. Up to now, the impact of any ethnic or geographical factor on 
its incidence has not been reported. Because of misdiagnosing of mild cases, these 
conditions may be presumed as idiopathic thrombocytopenia purpura [4].
4. Clinical and pathological manifestations
4.1 Incidence and clinical phenotypes
The incidence of the classic WAS phenotype has been estimated at 1 in 100,000 
individuals. Based on clinical manifestations, WAS-XLT commonly is presented 
at birth and consists of bruising, bloody diarrhea as well as petechiae. Excessive 
bleeding consequent circumcision can be considered as an early diagnostic sign. 
Furthermore, during infancy and childhood, eczema is a frequent manifestation 
of patients with classic WAS. Small platelet and thrombocytopenia are the most 
reliable finding in WAS and XLT phenotype. A variety of infections such as bacte-
rial pneumonia, skin infections as well as otitis media with drainage of mucoid 
material are common complaints. XLT patients are less likely to have problems such 
as eczema and infection and oftentimes are misdiagnosed with Idiopathic throm-
bocytopenic purpura (ITP). Patients with X-linked neutropenia caused by mis-
sense mutations in the Cdc42-binding domain are affected at birth. However, their 
symptoms do not resemble those of classic WAS or XLT. Through a simple scoring 
system, we have delineated different clinical phenotypes (Table 1).
4.2 Thrombocytopenia
It is the foremost common finding present at the time of diagnosis and appears 
at birth. However, the severity is variable. Approximately 50% of patients with 
WAS will have severe Thrombocytopenia with a platelet count<20,000/μL. 
Furthermore, the severity of Thrombocytopenia has a close relationship with bleed-
ing. Bleeding events occur in >80% of WAS patients. These bleeding complications 
consist of non-life-threatening (e.g, ecchymosis, hematemesis, epistaxis, petechiae, 
etc.) and or life-threatening (eg, gastrointestinal and intracranial hemorrhage). 
life-threatening bleeding happens in 30% of patients. However, intracranial hemor-




normal in patients with WAS, platelet formation changes into abnormal. It should 
be noted that the role of anti-platelet antibodies in platelet destruction and main-
taining thrombocytopenia isn’t negligible. As an example, a group of infants less 
than or equal to 2 years of age may present with “severe refractory thrombocyto-
penia,” probably due to antiplatelet autoantibody. Moreover, disruptions in platelet 
function as well as remarkable and may give rise to bleeding and diminished platelet 
survival. WASp plays a key role in the process of platelet formation, activation, and 
associated cytoskeletal remodeling so that failure in platelet production and func-
tion is attributed to it. Increased expression of phosphatidylserine on the surface 
of circulating platelets has been interpreted as a sign of increased phagocytosis and 
destruction of platelets within the spleen in WAS/XLT. Whereas, decreased platelet 
production resulting from ineffective thrombocytopoiesis [6–8].
4.3 Immunodeficiency
Abnormalities in immune system function (i.e., cell-mediated, humoral, and 
innate immunity) among patients with WAS give rise to vulnerability to a wide 
range of infections pathogens. Nevertheless, infectious complications as a primary 
manifestation are not frequent (<5% of cases). Opportunistic infections such 
as molluscum contagiosum infections, extensive candidiasis, aspergillosis, and 
WAS XLT IXLT XLN
Phenotype
Thrombocytopenia + + (+) -
Small platelets + + + -
Eczema +/++/+++ -/+ - -




Frequent Possible - -
Congenital neutropenia - - - +
Disease scores 3,4, or 5 1,2, or (5)† <1 0








IVIG Yes No (with exceptions) No No
HSCT Yes at an 
early age
Might be considered if 
there is a sibling donor
No ?
Splenectomy No Might be considered‡ No No
IXLT, Intermittent XLT; HSCT, hematopoietic stem cell transplantation; XLN, X-linked neutropenia.
Scoring system: -/ (+), absent or mild; -/+, intermittent thrombocytopenia; (+), mild, transient eczema or mild, 
infrequent infections not resulting in sequelae; +, thrombocytopenia, persistent but therapy-responsive eczema, and 
recurrent infections requiring antibiotics and often IVIG prophylaxis; ++, eczema that is difficult to control and 
severe, life-threatening infections.
*Infections typical for neutropenia.
†Patients with XLT with a score of 1 or 2 might progress to a score of 5. Incidence of autoimmunity and malignancies 
are less in XLT than in WAS.
‡Splenectomy results in increased platelet numbers and reduced bleeding but causes a marked increase in sepsis, 
requiring continuous antibiotic prophylaxis.
Table 1. 
Clinical phenotype associated with mutations of the WASP gene [acc.19].
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Pneumocystis jirovecii may also present in WAS patients [5, 9, 10]. Patients with 
WAS can suffer from severe and disseminated forms of herpes simplex virus I or 
II (6% of cases) and varicella (3% of cases) as the most widespread pathogens. In 
10% of cases, Invasive yeast and fungal infections have been reported. Generally, 
Sinopulmonary infections are classified as the most common infectious manifesta-
tion before diagnosis, including otitis media (64% of cases) and pneumonia. Other 
severe infectious complications are less likely to occur, such as sepsis (7% of cases) 
and meningitis (4% of cases) [6]. However, Viral infections caused by pathogens 
such as EBV, CMV, and HPV can be extremely severe.
In WAS patients, both quantitative and qualitative defects in T cells are mani-
fested T cell lymphopenia as a common disorder is seen more in naive T lympho-
cytes than in memory cells and CD8. This event may result from increased apoptosis 
and can appear from early life and subsequently affect thymic output [11, 12]. More 
often than not, WAS patients have got an absolute lymphocyte count >1,000/μL, 
demonstrating the lack of the profound lymphopenia seen in other primary immu-
nodeficiency disorders. Of note, an absolute lymphocyte count of <1,000/μL was 
presented in only 22% of cases. Processes such as T-cell activation, chemotaxis, and 
cytokine secretion are disturbed in patients with WAS [13, 14].
Humoral immunodeficiency is another characteristic of WAS patients. High 
serum levels of IgE and Low levels of IgM, IgG, and IgA are observed [5]. Abnormal 
isohemagglutinin titers (84% of cases) and insufficient vaccine responses to protein 
(e.g., 62% with abnormal responses to tetanus vaccine), polysaccharide (e.g., 69% 
with abnormal responses to the pneumococcal vaccine), and conjugate vaccines 
(e.g., 66% with abnormal responses to Hib (Haemophilus influenzae type b) conju-
gate vaccines, implies that antibody responses may be abnormal [5]. Malfunctions 
in T-cell mentioned earlier may disturb the maturation and differentiation of B cells 
into antibody-producing cells and memory cells [15].
Perturbations in the components of the innate immune response may also be 
present. The number of Natural Killer (NK) cells can be in the normal range or 
increase. Nonetheless, most of the time, NK cell function is abnormal, includ-
ing Immunological synapse formation, stimulation of secretory granules, and 
consequent cytolytic activity [16]. Despite the normal numbers of neutrophils, 
monocytes, and other phagocytes, functional abnormalities may be present in 
WAS patients. Chemotaxis, adhesion/arrest function, DC motility, the initiation 
of degranulation, the formation of a functional respiratory burst, and antibody-
mediated phagocytosis are more likely to be impaired [17, 18].
4.4 Eczema
Eczema is one of the specific findings that essentially leads to the differentiation 
of WAS from ITP. Skin manifestations resemble acute or chronic eczema in appear-
ance and distribution. Eczema of varying severity occurs in approximately 50% of 
WAS patients during the first year of life and resembles classic atopic dermatitis. 
[2]. According to a large cohort study, 81% of WAS patients are classified into mild 
or severe, transient, or consistent, depending on their eczema history. In severe 
form, eczema resists therapy and lasts into adulthood. Based on some statistical 
evidence, Patients with XLT either have mild transient eczema or do not have any of 
these symptoms. It has been hypothesized that defects in the chemotaxis of DC and 
Langerhans cells, which are responsible for presenting specific (probably bacte-
rial) antigens to T lymphocytes, cause eczema. Eczema is more complex in families 
with a history of atopic disease because the findings suggest that genes involved in 





According to collected data, autoimmunity is a frequent occurrence in patients 
with WAS. Reports indicate that 40% of patients with WAS develop autoimmunity 
and that many patients show various forms of autoimmune disease. A study affirms 
that Two-thirds of WAS patients who show autoimmune manifestations develop 
multiple autoimmune disorders. Autoimmune hemolytic anemia (14%), vasculitis 
(13%), renal disease (12%), and chronic arthritis (10%) are the most common mani-
festations of autoimmunity in WAS [5]. Autoimmunity in WAS may be due to the 
formation of autoantibodies or the presence of autoreactive T cell clones. Moreover, 
disorders in the homeostasis of regulatory T cells and B lymphocytes can lead to 
autoimmune disorders in WAS patients. Generally, the incidence of autoimmune 
disease is lower XLT than in classic WAS. A broad spectrum of autoantibodies has 
been detected both in classic WAS and in XLT. For example, high serum IgM levels 
are a risk factor for the development of autoimmune disease and early death [21, 22].
4.6 Malignancies
Malignancies can occur during childhood, whereas it is most likely to appear in 
adolescents and young adults with the classic WAS phenotype. B cell lymphoma 
(often Epstein-Barr virus-positive), leukemia, myelodysplasia, and myeloprolifera-
tive disorders are among the most frequent malignancies [6, 23]. Based on a cohort 
study, 13% of patients with WAS developed malignancy at a mean age of 9.5 years, 
and only 1 of 21 patients who developed a malignancy was alive more than two years 
after diagnosis [5]. The incidence of malignancies in patients with XLT phenotype is 
ambiguous and less than in classic WAS. In WAS patients, the prevalence of non-
Hodgkin lymphoma (NHL) is more common than Hodgkin lymphoma (HL) [23]. 
Several NHL, such as Burkitt lymphoma and lymphoblastic lymphoma, have been 
reported rarely among patients with WAS. The aggressive nature of malignancy in 
the WAS patients represents a poor prognosis, as data demonstrate 95% mortality 
among patients. It should be noted that genetic susceptibility due to malfunction of 
WASp, associated abnormalities in tumor-surveillance mechanisms (e.g., impair-
ment in NK cell cytotoxicity), and environmental factors (e.g., Epstein–Barr virus 
[EBV]) are significant components that increase the risk of malignancy in patients 
with WAS [24].
4.7 X-linked thrombocytopenia and X-linked neutropenia
XLT is assumed as congenital thrombocytopenia that is sometimes intermittent 
(IXLT). In such cases, the eczema is usually mild. Generally, XLT patients have got a 
benign disease as well as excellent survival in contrast to patients with WAS. serious 
hemorrhage in 13.9%, life-threatening infections in 6.9%, autoimmunity in 12.1%, 
and malignancy in 5.2% of XLT patients at median ages of 4.9 years, 24.8 years, 12.2 
years, and 34.0 years, respectively. Every male with thrombocytopenia and small 
platelets should be evaluated for WASp expression and WAS gene mutations [25].
XLN presents mainly as a congenital and severe form of neutropenia. Unlike 
WAS, infectious complications due to T-cell immunodeficiency are absent. 
Impairments in immune function are similar to those explained for WAS. 
Nevertheless, Decreased NK cell count is a valid finding in XLN patients. Also, a 
slight decrease in platelet count has been reported. The potential risk of myelo-
dysplastic syndrome and chronic myelocytic leukemia exists, which needs regular 
surveillance [26].
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5. Histopathology
Gradually, the cellular elements in the thymus and lymphatic organs begin to 
disappear [27]. Depletion of small lymphocytes from T cell areas, reticular cell 
stroma protrusions, and the presence of abnormal plasma cells, often associated 
with extracellular plasmacytosis and hematopoiesis, are consistently seen in the 
lymph nodes and spleen of patients with WAS [28]. In a study of spleens obtained 
from WAS patients undergoing splenectomy, gradual depletion of the marginal 
zone involving B cells was also observed [29]. It may be possible to justify the dis-
ruption of the antibody response to selected polysaccharides and protein antigens 
by examining these histological abnormalities.
6. Diagnosis
WAS is an X-linked disease presented in males, with a lack of clinical symptoms 
in female carriers. Also, a deleterious mutation of the paternally derived X chro-
mosome and inactivation of the maternally derived X chromosome lead to WAS 
in females, which is rare [30]. The diagnosis of WAS should be conducted in any 
male appearing with thrombocytopenia, eczema, recurrent respiratory infections, 
autoimmunity, etc (Table 2). Clinical findings may or may not be present during 
the course of the disease. Therefore, Because of evolution in clinical, physical, and 






Bleeding Mucosal bleeding (easy bruising, epistaxis, hematochezia, hematuria) 
or intracranial hemorrhage
Infections Recurrent or severe sinopulmonary infections, viral infections, fungal 
infections, or opportunistic infections




X-linked disorder Every generation affected; predominant male susceptibility
Laboratory exam
Complete blood cell count Anemia, microcytosis, thrombocytopenia, low mean platelet volume
Peripheral blood smear Microthrombocytes
Serum IgG, IgA, IgM, and IgE Low lgG, lgA, lgM; high lgE
Isohemagglutinin and vaccine 
titers
Abnormal isohemagglutinin titers and diminished vaccine responses to 
protein, polysaccharide, and conjugate vaccines
Lymphocyte subsets and 
mitogen responses
T-cell lymphopenia and abnormal proliferative responses to mitogens
Abbreviation: Ig, immunoglobulin.
Table 2. 




Despite the broad spectrum of clinical features, there is a considerable association 
between genotype and phenotype [9]. Mutations give rise to absent WASp expression 
and residual WASp expression are related to classic syndrome and XLT phenotype 
respectively. Also, gain-of-function mutations in the WAS gene result in XLN [31].
Interestingly, the patient phenotype may undergo genetic reversion, a selective 
advantage that can produce hematopoietic cells with normal WASP expression [32]. 
Screening for WASP mutations can be accomplished by flow cytometry using a suit-
able anti-WASP antibody. With this method, patients with expression of mutated 
WASP are likely to be miss. However, scrutinizing Sequence analysis of the WASP 
gene is essential to establishing a final diagnosis. It is speculated that the combina-
tion of two methods may help to estimate the severity of the disease [7].
7. Prognosis
The prognosis of X-linked thrombocytopenia has got a favorable position with 
a life expectancy close to the normal population [25]. Whereas, Classic Wiskott 
Aldrich syndrome has a poor prognosis with decreased life expectancy, which 
can be attributed to recurrent infections, autoimmune disease, and malignancy. 
Hemorrhage is the main cause of death in these patients [5].
As soon as a diagnosis is confirmed, the patient should be monitored and evalu-
ated in a center with expertise in the management of WAS. It is clear that Without 
appropriate care and intervention, morbidity and mortality will not be unexpected. 
In a retrospective research, it has been demonstrated 36% of patients with WAS 
experienced non-HSCT-associated deaths at a mean age of 8 years. Mainly, these 
deaths are caused by infection (44%), bleeding (23%), and malignancy (26%) [5].
Many centers that provide look after WAS patients have multifaceted approaches 
to the care of patients and affected members of family, including genetic counsel-
ing, psychosocial support services, and subspecialist support, like transplant immu-
nology, hematology/oncology, communicable disease, and important care. Of note, 
with appropriate care and timely intervention, WAS patients have an interesting 
prognosis. As an example, long-term survival following the utilization of allogeneic 
HSCT is >80% [31].
8. Treatment
Basically, the treatment of Wiskott-Aldrich syndrome depends on supportive care 
which includes Broad-spectrum antibiotics for bacterial, fungal, or viral infections. 
Furthermore, platelet supplement, Topical steroids and prevent bleeding, are other 
treatments. However, a series of controversial treatment are as follows (Table 3).
8.1 Intravenous Immunoglobulin  therapy
Intravenous immunoglobulin (IVIG) therapy in WAS and XLT patients with 
significant antibody deficiency has led to efficient results. IVIG should be admin-
istered at physiological doses to patients with recurrent infectious complications 
and low levels of immunoglobulin or abnormal antibody responses [6]. Because 
of the increasing catabolic rate observed in WAS patients, the dose is higher than 
other immunodeficiency diseases. Since these people are more likely to bleed, 
a Subcutaneous injection of the IVIG is recommended [33]. In the presence of 
autoimmune manifestations, at least intermittently, immunosuppressive therapy 
may be required.
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8.2 Splenectomy
Splenectomy is used to slow down the process of thrombocytopenia and stop 
bleeding by increasing the number of circulating platelets. Patients undergoing 
splenectomy consume antibiotics for life also they are highly vulnerable to sep-
ticemia [2]. Splenectomy is not recommended for people who are going to have 
Hematopoietic cell transplantation (HCT) in the future because it increases the risk 
of significant infectious complications [6, 7].
8.3 Eltrombopag
It is an oral thrombopoietin receptor agonist approved for the treatment of ITP 
which is claimed to probably effective in preventing bleeding in patients with WAS 
waiting for HCT [34].
8.4 Immunosuppressive treatment
More often than not, prescribing immunosuppressive drugs (e.g., cyclophos-
phamide, azathioprine) is necessary for the autoimmune phenomenon [35]. Most 
of the time, Monoclonal antibody rituximab may be effective in cytopenias due to 
Autoimmune disorders and it should be noted that the aforementioned antibody 
partly is harmless for patients already receiving therapy with IVIG [2].
8.5 Hematopoietic cell transplantation (HCT)
In a way, it can be said HCT is a unique treatment for patients with human 
leukocyte antigen (HLA)-matched family or unrelated donors (URDs) or relatively 
matched cord-blood donors [2].
Newly, according to haploidentical donors, novel graft manipulation approaches 
that alleviate the risk of graft versus host disease (GVHD) and elevate the pos-
sibility of successful engraftment, as well as immune system reconstruction, have 
yielded promising results in patients with WAS [36]. Reports indicate that The older 
you are at the time of transplantation, the lower your chances of survival, with dif-










Hematopoietic cell transplantation (HCT)
Gene therapy
Table 3. 




Despite the high chance of survival after transplantation for WASP patients, 
these patients are still at risk for post-HCT complications, among which autoim-
munity is a prominent problem. It has been reported that up to 55% of transplanted 
WAS subjects develop autoimmune manifestations, mostly involving antibody-
mediated cytopenias [39–42]. Although the risk of death in HCT is inevitable, 
according to a pervasive theory, patients with the severe phenotype (clinical score 3 
and above) should be transplanted. For WAS patients with milder clinical manifes-
tations, there is no unanimous opinion, and the decision to continue HCT is made 
on a case-by-case basis. The results of the decision-making process were the result 
of a retrospective study of the outcome of HCT in a group of 24 milder patients 
between 1990 and 2011 who were transplanted at various centers around the world. 
This study indicated a survival rate of 83% in the absence of long-term complica-
tions [43].
8.6 Gene therapy
Approximately, HCT from HLA-identical family donors is available to less than 
20% of transplanted WAS patients [40, 43]. Although this approach is evolving 
[36], the increasing complications and mortality of HCT from mismatched donors 
[40] provide the idea for research into alternative kinds of gene therapy. Gene 
therapy prepares an enormous of potential advantages over allogeneic HCT, includ-
ing availability for all patients, reduce transplant rejection risks and prevent GVHD 
risks, which successively eliminates the necessity to follow special diets and take 
immunosuppressive drugs. For the primary time in Germany, gene therapy for WAS 
was accomplished in a clinical trial, during which a gamma-retroviral vector was 
used to correct CD34+ cells from ten WAS patients. As a result of this investigation, 
nine of those individuals showed a significant increase in platelet count and reha-
bilitation of immune responses. But unfortunately, seven patients developed acute 
leukemia related to vector integration-mediated activation of the LMO2, MDS1, or 
MN1 genes [44, 45].
A High and unacceptable rate of cancer incidence in gamma-retroviral gene 
therapy paves the way for the implementation of clinical gene transfer protocols 
using HIV 1-based constructs [46]. Currently, a series of clinical trials in Europe 
and the U.S. using these lentiviral vectors have yielded encouraging preliminary 
results In 2010, when the primary trial was launched, Italian investigators have 
treated a minimum of 10 patients (F. Ferrua, personal communication, Barcelona, 
September 2016) with infusions of gene-corrected bone marrow and/or mobilized 
peripheral blood CD34+ hematopoietic cells. Then, they controlled the possible 
side effects by prescribing busulfan, fludarabine, and rituximab. The results of the 
first three patients ≥ 1 year after gene therapy indicated an improvement in platelet 
count and immune cell function additionally a reduction in severe infections and an 
improvement in eczema [47, 48]. The results of studies on the effect of gene therapy 
on defective B cells in patients with WAS indicate that standard distribution of bone 
marrow and peripheral blood cell subsets, in treated patients, is achievable. most 
significantly, a serious decrease within the abundance of naive B cells producing 
reactive antibodies, which are involved in improving the quantity of circulating 
antibodies altogether treated patients, was observed [49, 50].
The second investigation, conducted in London and Paris, using the identical 
lentiviral vector and a uniform reparative chemotherapy regimen, 6 out of seven 
patients treated also demonstrated improvement of immune function and clinical 
manifestations during 6–42 months of follow-up. Furthermore, during this study, 
no vector-mediated clonal expansions have occurred [51]. Of note, although in both 
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trials the duration of bleeding was significantly reduced in number and severity, 
and also the treated patients not needed blood transfusions and thrombopoietin 
receptor agonists, platelet counts failed to normal in either trial that it isn’t clear. 
The third trial of WAS gene therapy supported lentiviral vector has recently begun 
in Boston, USA [52]. At the identical time, other US researchers have developed an 
alternate lentiviral vector with a stronger WASp expression that’s being developed 
for future clinical applications [53, 54].
In line with current studies, it will be acknowledged that gene modification by 
lentivirus from autologous hematopoietic ancestors can have significant benefits 
for patients undergoing treatment and be considered as treatment options for WAS. 
However, more comprehensive studies are needed to ascertain whether this type of 
gene therapy could also be a definitive treatment for patients.
9. Conclusions
Despite the rarity of WAS, extensive progress has been made in understanding 
its pathophysiological foundations, but it is still necessary to establish multifac-
eted management to assess various aspects of the disease. It is worth noting that 
health care centers have been pioneers in the diagnosis and management of WAS. 
Significant advances in allogeneic HCT and its valuable long-term results have made 
it a viable treatment option for most patients with WAS. For severe manifestations, 
for example, definitive treatment with HCT is recommended. However, even in a 
clear clinical situation, HCT may not be available due to the patient’s geographical 
location or socioeconomic status, so supportive care measures should be taken 
promptly. The same is true of WAS cases with milder clinical manifestations; In 
fact, more emphasis is placed on accepting the potential risks of treatment in 
proportion to the severity of the disease manifestations.
Gene therapy is a potential treatment solution for WAS patients with severe 
and even mild phenotypes. In this regard, the emergence of advances in the use of 
gene editing technology creates a cautious optimism. However, the financial and 
geographical problems for patients with limited access to gene therapy options need 
to be addressed.
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